Transparency push, Danaher's Masimo play & 340B reform
Supply Chain Pulse — 2026-06-30
Two bipartisan bills advancing in Congress would mandate new layers of healthcare supply chain transparency — and HSCA is already on record in support, signaling this has real momentum heading into Q3. Meanwhile, Danaher's finalized acquisition of Masimo reshuffles the patient monitoring market just as health systems are accelerating their pivot toward outpatient and ASC settings, adding complexity to device contracting on both ends. Layer in a Senate proposal to overhaul 340B with rebate mechanics and fresh federal oversight, and today is essentially a stress-test day for every strategic assumption you made in your 2026 sourcing plan. If you haven't flagged the 340B bill for your pharmacy and contracting teams yet, today is the day.
Quick Hits
- Oregon health system cuts 45 leadership roles in latest sign of health system cost pressure — layoffs and closures tracker continues to grow. (Modern Healthcare)
- CMS published its full fact sheet on the new accrediting organization oversight rule — worth bookmarking for your compliance and regulatory affairs teams. (CMS Newsroom)
- CMS press release officially confirms the accrediting organization accountability rule is finalized, effective immediately. (CMS Newsroom)
HSCA Backs Bipartisan Bills to Boost Supply Chain Transparency
HSCA and its GPO members are formally supporting two bipartisan Congressional bills aimed at increasing visibility across the healthcare supply chain — a rare show of unified industry backing that suggests these proposals have a credible path forward. For supply chain leaders, greater transparency mandates could reshape how GPO contracts, supplier relationships, and pricing data are disclosed and audited. Start watching for how your distributors and vendors begin positioning on compliance readiness.
Source: Healthcare Supply Chain Association (HSCA)
Danaher Closes Masimo Acquisition, CEO Steps Down
Danaher finalized its acquisition of Masimo, making the patient monitoring company a wholly owned subsidiary — and CEO Katie Szyman is stepping down in the transition. For supply chain and value analysis teams, this is a prompt to review Masimo contracts and assess how Danaher's integration strategy may affect pricing, service terms, and product roadmaps. Danaher has a well-documented playbook for post-acquisition standardization; don't wait for your rep to bring it up.
Health Systems Are Buying ASCs, Not Hospitals — Here's Why It Matters
Facing reimbursement pressure and regulatory headwinds, health systems including Ascension, CommonSpirit, and Lahey are pivoting M&A strategy toward outpatient and ambulatory surgery center acquisitions rather than traditional hospital deals. For supply chain teams, this shift means more decentralized care settings to serve, more SKU variation across sites, and ASC-specific contracting demands that your hospital-centric GPO agreements may not cover cleanly. This trend accelerates the case for building an outpatient supply chain strategy that's distinct from your acute care model.
Key GOP Senator Proposes 340B Overhaul with Rebate Model
Senate HELP Committee Chair Bill Cassidy (R-La.) introduced a bill that would restructure the 340B Drug Pricing Program around a rebate-based model and give regulators new oversight authority over covered entities and contract pharmacies. For health systems and hospital pharmacies that rely heavily on 340B savings — which can run tens of millions of dollars annually for large systems — this proposal is a material financial risk worth escalating to your CFO now, not when it passes. The rebate shift in particular could create significant cash flow timing disruptions even if net savings remain nominally intact.
CMS Finalizes Rule Tightening Oversight of Hospital Accrediting Organizations
CMS finalized a rule enhancing accountability standards for nine hospital accrediting organizations, including The Joint Commission, giving the agency more direct oversight authority over how these groups conduct surveys and enforce compliance. Supply chain teams often underestimate accreditation's downstream effect on operations — from sterile processing standards to device storage and documentation requirements — and tighter CMS oversight means surveyors may scrutinize these areas more rigorously. Use this as a trigger to audit your compliance documentation for supply-related standards before your next survey cycle.
TempraMed Expands McKesson Medical-Surgical Partnership for Full Portfolio Distribution
TempraMed Technologies has expanded its strategic partnership with McKesson Medical-Surgical to distribute its full product portfolio across B2B channels in North America, accelerating its growth in temperature-sensitive medication management. For supply chain and pharmacy teams, this means TempraMed's cold-chain and insulin protection products will be more broadly accessible through McKesson's distribution network — worth evaluating if your formulary management or patient education programs include temperature-sensitive medications. Distributor-backed launches like this often come with introductory contract pricing, so engage your McKesson rep early.
Source: GDELT - Healthcare Supply Chain
FDA Warns Companies on Falsified Test Data; HHS Floats Drug Acceleration Plan
This week at FDA: HHS proposed new initiatives to accelerate drug approvals, while FDA issued warnings to companies found falsifying test data — a stark reminder that quality integrity remains under active regulatory scrutiny. For supply chain teams managing approved supplier lists and vendor qualification programs, FDA data falsification warnings are an actionable signal to review your supplier audit cadence, particularly for any manufacturers flagged in recent 483 observations. The HHS acceleration proposals, if finalized, could also shorten timelines for new drug entries — which has both opportunity and substitution risk implications for your formulary.
Source: GDELT - Healthcare Supply Chain
Defending Batch Integrity: What Pharma Manufacturers Are Prioritizing
A new analysis in PharmaTimes examines how pharmaceutical manufacturers are strengthening batch integrity processes in response to heightened regulatory and quality expectations. For hospital supply chain and pharmacy teams, batch integrity failures upstream translate directly into recalls, substitutions, and formulary disruptions — and understanding manufacturer quality priorities can inform smarter supplier risk tiering. This is particularly relevant as FDA scrutiny of falsified test data intensifies (see above).
Source: GDELT - Healthcare Supply Chain
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe